Pulsenmore Ltd. appointed David Woods, a med-tech veteran with over 25 years of experience including roles at Creo Medical and PENTAX Medical Americas, as its new Chief Commercial Officer (CCO). The appointment accompanies an expansion of the company's U.S. commercial team to accelerate growth in the American healthcare market following FDA De Novo authorization for its home prenatal ultrasound system. Pulsenmore aims to leverage Woods' expertise to scale operations, deepen a strategic collaboration with Ouma Health, and capitalize on opportunities within the federal Rural Health Transformation Program. The company develops patient-operated ultrasound systems that enable remote clinical assessment and monitoring for pregnancy and fertility care.
